DXCM February 2026 Options Begin Trading

DexCom (DXCM) option ideas: selling a $60 put (bid $1.00) against the $67.41 stock would set an effective cost basis of $59.00 and is ~11% out‑of‑the‑money, with analytics putting a 75% chance it expires worthless and a 1.67% return (13.83% annualized) if so. Alternatively, a covered call using the $71 strike (bid $2.00, ~5% OTM) would produce an 8.29% total return to Feb 2026 if called and is estimated to have a 58% chance to expire worthless, yielding 2.97% (24.61% annualized) if it does. Implied volatilities are 58% for the put and 48% for the call versus a 12‑month realized volatility of 45%, highlighting elevated option premia that could appeal to income-oriented option sellers.

Analysis

Market structure: The option quotes imply a moderately bullish-but-cautious market for DXCM — $60 puts trading at $1 imply a 11% OTM cash‑secured entry point with ~75% chance to expire worthless, while $71 calls at $2 price ~5% upside with ~58% odds to expire worthless into Feb 2026 (~1.5 months). Implied vols (48–58%) exceed 45% realized, signaling option sellers are being compensated for event risk; this compresses financing cost for buyers of delta exposure and makes short‑premium strategies attractive if gamma risk is controlled. Cross-asset: a large negative move in DXCM could bid implied vol across medtech names, press risk premia in high‑yield corporates and modestly tighten diabetes-equipment spreads versus broader healthcare equities.

Risk assessment: Tail risks include an FDA adverse action, a major competitor reimbursement win (e.g., Abbott/ABT winning broader payer coverage), or manufacturing recall — any of which could knock DXCM >25% in weeks. Near term (days–weeks) price is option‑flow sensitive around earnings and any Feb 2026 catalyst; medium (3–12 months) risks hinge on reimbursement and CGM adoption curves; long term depends on integration with insulin delivery and international rollout. Hidden dependencies: revenue tied to payer policy changes and sensor durability; inventory cycles can exaggerate sequential prints. Key catalysts: DXCM earnings, CMS/payer rulings, Abbott product announcements in 30–90 days.

Trade implications: Favor defined‑risk premium selling rather than naked directional exposure: cash‑secured $60 put or a $60/$55 bull‑put spread for Feb 2026 captures elevated IV and offers effective entry near $59 with capped downside (max loss ~$400 per spread per $1 credit). For equity exposure, buy DXCM and sell the $71 Feb 2026 call (covered call) to target an ~8–9% capped return to expiry; use covered calls only as part of 1–3% portfolio tactical themes. Volatility view: sell skewed put spreads instead of naked puts given asymmetric put IV (58% vs 48%).

Contrarian angles: Consensus treats DXCM as a growth device name — that underprices regulatory/reimbursement binary risk, so selling a small-sized put spread is underdone protection. Conversely, if DXCM posts conservative guidance and IV collapses toward 35–40%, long calendar or long calls (buy 71s) could be mispriced — consider buying cheap long-dated calls after IV drops. Historical parallels: medtech winners often gap down on single‑quarter disappointments but recover over 6–12 months if tech leadership intact; use that to size mean‑reversion plays, not levered directional bets.

Key Decisions for Investors

• Establish a tactical 1–2% portfolio position in DXCM by selling one Feb 2026 $60 cash‑secured put per $6,000 notional (collect ~$100); if assigned, basis ~ $59; initial position size max 2% of portfolio and set hard stop to exit/hedge if DXCM < $50 within 30 days.
• Prefer defined‑risk alternative: sell Feb 2026 $60/$55 bull‑put spreads sized to 1% portfolio (target credit ≥ $0.80–$1.20); max loss = $400–$420 per spread; roll or close if DXCM trades below $57 with IV >60%.
• If owning shares, implement covered calls: buy DXCM up to 1–2% portfolio and sell Feb 2026 $71 calls to pocket ~$200 per contract; set target to let be called at $71 (realize ~8–9%) or buy back if DXCM > $75 before expiry to avoid assignment.
• Relative‑value pair: overweight DXCM vs underweight ABT (long DXCM 1–2%, short ABT 1–2%) for 6–12 months to express CGM share gain thesis; trim if DXCM fundamental guidance misses or if ABT announces major payer wins.
• Avoid naked short puts larger than 2% portfolio and monitor these triggers in next 30–60 days: DXCM earnings release, CMS/payer announcements, Abbott product news; tighten stops/convert to spreads on any negative regulatory headlines.